RECURRENT ENDOMETRIAL CARCINOMA

This early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in about 31 people whose endometrial, ovarian, or related cancers have returned. The main goal is to find the safest dose and understand side effects. Participants must have ce…

This early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…

This study tests whether adding a third drug (ribociclib) to a two-drug combination (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. The trial involves 90 participants and aims to see if the three-drug combo can shrink tumors or st…

This study tests a new three-drug combination (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the combination shrinks tumors and to check for si…

This early-phase trial tests a specially designed virus (VSV-hIFNbeta-NIS) that is meant to infect and kill cancer cells while leaving healthy cells alone. It is given intravenously to people with stage IV or recurrent endometrial cancer. The main goals are to find the safest dos…

This study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combination could slow or stop cancer growth. Participants had already tried other treatments and their ca…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without the cancer growing. About 813 participants with stage III, IV, or recurrent di…